Tiziana Life Sciences (TLSA) Competitors $1.29 -0.07 (-5.15%) Closing price 04:00 PM EasternExtended Trading$1.29 0.00 (0.00%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLSA vs. CDXC, PHAR, ORGO, CRMD, BCYC, IMTX, KROS, AKBA, VECT, and COGTShould you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include ChromaDex (CDXC), Pharming Group (PHAR), Organogenesis (ORGO), CorMedix (CRMD), Bicycle Therapeutics (BCYC), Immatics (IMTX), Keros Therapeutics (KROS), Akebia Therapeutics (AKBA), VectivBio (VECT), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry. Tiziana Life Sciences vs. ChromaDex Pharming Group Organogenesis CorMedix Bicycle Therapeutics Immatics Keros Therapeutics Akebia Therapeutics VectivBio Cogent Biosciences ChromaDex (NASDAQ:CDXC) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, community ranking, valuation and profitability. Do insiders and institutionals hold more shares of CDXC or TLSA? 15.4% of ChromaDex shares are owned by institutional investors. 9.6% of ChromaDex shares are owned by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts recommend CDXC or TLSA? ChromaDex presently has a consensus target price of $9.03, suggesting a potential upside of 0.00%. Given ChromaDex's stronger consensus rating and higher probable upside, analysts plainly believe ChromaDex is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ChromaDex 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, CDXC or TLSA? ChromaDex has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Is CDXC or TLSA more profitable? ChromaDex has a net margin of 1.62% compared to Tiziana Life Sciences' net margin of 0.00%. ChromaDex's return on equity of 4.85% beat Tiziana Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets ChromaDex1.62% 4.85% 2.70% Tiziana Life Sciences N/A N/A N/A Does the MarketBeat Community believe in CDXC or TLSA? ChromaDex received 459 more outperform votes than Tiziana Life Sciences when rated by MarketBeat users. Likewise, 64.91% of users gave ChromaDex an outperform vote while only 63.58% of users gave Tiziana Life Sciences an outperform vote. CompanyUnderperformOutperformChromaDexOutperform Votes55564.91% Underperform Votes30035.09% Tiziana Life SciencesOutperform Votes9663.58% Underperform Votes5536.42% Which has stronger earnings & valuation, CDXC or TLSA? ChromaDex has higher revenue and earnings than Tiziana Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChromaDex$99.60M0.00-$4.94M$0.10N/ATiziana Life SciencesN/AN/A-$17.69MN/AN/A Does the media prefer CDXC or TLSA? In the previous week, Tiziana Life Sciences had 1 more articles in the media than ChromaDex. MarketBeat recorded 2 mentions for Tiziana Life Sciences and 1 mentions for ChromaDex. Tiziana Life Sciences' average media sentiment score of 0.11 beat ChromaDex's score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment ChromaDex Neutral Tiziana Life Sciences Neutral SummaryChromaDex beats Tiziana Life Sciences on 12 of the 15 factors compared between the two stocks. Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLSA vs. The Competition Export to ExcelMetricTiziana Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$150.73M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.3222.5118.54Price / SalesN/A241.49397.62103.34Price / CashN/A65.8538.1834.62Price / Book25.806.486.734.25Net Income-$17.69M$143.41M$3.22B$248.18M7 Day Performance-10.42%2.30%1.58%1.25%1 Month Performance21.70%7.14%4.05%3.76%1 Year Performance94.74%-2.61%15.75%5.28% Tiziana Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLSATiziana Life Sciences0.4707 of 5 stars$1.29-5.1%N/A+110.0%$150.73MN/A0.008Short Interest ↑News CoverageCDXCChromaDex2.3292 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120Upcoming EarningsAnalyst ForecastPHARPharming Group2.5184 of 5 stars$8.75+2.8%$30.00+242.9%-6.6%$595.27M$297.20M-33.65280Upcoming EarningsShort Interest ↓News CoveragePositive NewsORGOOrganogenesis3.4229 of 5 stars$4.67+2.4%$5.50+17.8%+108.9%$592.29M$482.04M-77.83950Upcoming EarningsNews CoveragePositive NewsCRMDCorMedix2.4975 of 5 stars$9.06-0.4%$14.50+60.0%+74.9%$590.55M$43.47M-11.1930Upcoming EarningsPositive NewsBCYCBicycle Therapeutics3.0463 of 5 stars$8.40-0.2%$29.14+246.9%-63.5%$581.30M$35.28M-2.55240Analyst ForecastShort Interest ↓News CoveragePositive NewsIMTXImmatics2.0574 of 5 stars$4.77+5.5%$16.67+249.4%-49.6%$579.79M$155.84M-7.23260Positive NewsKROSKeros Therapeutics3.099 of 5 stars$14.26+0.4%$40.33+182.8%-74.4%$578.41M$3.55M-2.74100Upcoming EarningsPositive NewsAKBAAkebia Therapeutics4.0729 of 5 stars$2.43+2.1%$6.63+172.6%+91.3%$574.04M$160.18M-10.56430Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsGap UpVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeCOGTCogent Biosciences2.1846 of 5 stars$4.91+5.8%$14.43+193.9%-19.8%$559.03MN/A-1.9880Upcoming EarningsOptions VolumeAnalyst Revision Related Companies and Tools Related Companies CDXC Competitors PHAR Competitors ORGO Competitors CRMD Competitors BCYC Competitors IMTX Competitors KROS Competitors AKBA Competitors VECT Competitors COGT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLSA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThe Worst Year in American Financial History?Economist Explains: The Curse on the U.S. Dollar Yes, there is a Curse on the U.S. Dollar... and it's behin...Stansberry Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TLSA Stock Free TLSA Stock Alerts